899 resultados para Current hosusehold survey
Resumo:
Prepared for the Cache River Joint Venture Partnership (JVP): Illinois Department of Natural Resources, The Nature Conservancy, U.S. Fish and Wildlife Service, Ducks Unlimited, Natural Resources Conservation Service.
Resumo:
First ed. issued as its Special publication, no. 152.
Resumo:
Includes index.
Resumo:
"30 June 1986."
Resumo:
"22 April 1987."
Resumo:
Includes index.
Resumo:
Vols. for 1865-1876/77 have title: Report of the superintendent of the United States Coast Survey, showing the progress of the Survey during the year ...
Resumo:
Latest issue consulted: Apr. 1996.
Resumo:
"September 2003"--P. ii.
Resumo:
Title from cover.
Resumo:
Issues for Dec. 1988, July 1989 distributed to depository libraries in microfiche.
Survey of the federal government on supervisor practices in employment of people with disabilities /
Resumo:
Shipping list no.: 2003-0007-P.
Resumo:
Thesis (Ph.D.)--University of Washington, 2016-06
Resumo:
Background Mental health survey data are now being used proactively to decide how the burden of disease might best be reduced. Aims To study the cost-effectiveness of current and optimal treatments for mental disorders and the proportion of burden avertable by each. Method Data for three affective, four anxiety and two alcohol use disorders and for schizophrenia were compared in terms of cost, burden averted and efficiency of current and optimal treatment. We then calculated the burden unavertable given current knowledge. The unit of health gain was a reduction in the years lived with disability (YLDs). Results Summing across all disorders, current treatment averted 13% of the burden, at an average cost of AUS$30 000 per YLD gained. Optimal treatment at current coverage could avert 20% of the burden, at an average cost of AUS$18 000 per YLD gained. Optimal treatment at optimal coverage could avert 28% of the burden, at AUS$16 000 per YLD gained. Sixty per cent of the burden of mental disorders was deemed to be unavertable. Conclusions The efficiency of treatment varied more than tenfold across disorders. Although coverage of some of the more efficient treatments should be extended, other factors justify continued use of less-efficient treatments for some disorders. Declaration of interest None. Funding detailed in Acknowledgements.
Resumo:
Background. The present paper describes a component of a large Population cost-effectiveness study that aimed to identify the averted burden and economic efficiency of current and optimal treatment for the major mental disorders. This paper reports on the findings for the anxiety disorders (panic disorder/agoraphobia, social phobia, generalized anxiety disorder, post-traumatic stress disorder and obsessive-compulsive disorder). Method. Outcome was calculated as averted 'years lived with disability' (YLD), a population summary measure of disability burden. Costs were the direct health care costs in 1997-8 Australian dollars. The cost per YLD averted (efficiency) was calculated for those already in contact with the health system for a mental health problem (current care) and for a hypothetical optimal care package of evidence-based treatment for this same group. Data sources included the Australian National Survey of Mental Health and Well-being and published treatment effects and unit costs. Results. Current coverage was around 40% for most disorders with the exception of social phobia at 21%. Receipt of interventions consistent with evidence-based care ranged from 32% of those in contact with services for social phobia to 64% for post-traumatic stress disorder. The cost of this care was estimated at $400 million, resulting in a cost per YLD averted ranging from $7761 for generalized anxiety disorder to $34 389 for panic/agoraphobia. Under optimal care, costs remained similar but health gains were increased substantially, reducing the cost per YLD to < $20 000 for all disorders. Conclusions. Evidence-based care for anxiety disorders would produce greater population health gain at a similar cost to that of current care, resulting in a substantial increase in the cost-effectiveness of treatment.